{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:19Z","timestamp":1761871279717,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL007093"],"award-info":[{"award-number":["T32 HL007093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Histogenetics and the Seattle Translational Tumor Research Fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clml.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T02:55:38Z","timestamp":1552272938000},"page":"390-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience"],"prefix":"10.1016","volume":"19","author":[{"given":"Jason P.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirin","family":"Khajaviyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edus H.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda A.","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Till","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.003_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2019.03.003_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminoncol.2016.02.001","article-title":"Chronic lymphocytic leukemia: recent progress and current challenges","volume":"43","author":"Woyach","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2019.03.003_bib3","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2017.72.6810","article-title":"Chemoimmunotherapy is not dead yet in chronic lymphocytic leukemia","volume":"35","author":"Brown","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.003_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.003_bib5","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.003_bib7","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens vs. chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.03.003_bib9","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.03.003_bib11","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.003_bib12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.03.003_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20340","article-title":"Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia","volume":"79","author":"Lam","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.003_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4382.4382","volume":"128","author":"Eichhorst","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/leu.2015.227","article-title":"Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome","volume":"30","author":"Tambaro","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.003_bib17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib18","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2019.03.003_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2008.005157","article-title":"Therapy-related myeloid neoplasms","volume":"94","author":"Larson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.03.003_bib22","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.03.003_bib24","first-page":"2047","article-title":"Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia","volume":"8","author":"Robertson","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.003_bib25","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.003_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.003_bib27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bmt.2017.171","article-title":"Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome\/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party","volume":"52","author":"Scheid","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.003_bib28","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2017.33","article-title":"Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.003_bib29","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/leu.2017.238","article-title":"Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.03.003_bib30","first-page":"1199","article-title":"A\u00a0population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers","volume":"18","author":"De Roos","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2019.03.003_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bmt.2011.180","article-title":"Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy","volume":"47","author":"Zimmerman","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.03.003_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5234.5234","article-title":"Patients with therapy-related myelodysplastic syndromes (t-MDS) have shorter median overall survival than de novo MDS: Mayo Clinic Experience","volume":"126","author":"Hreh","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.003_bib33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:34Z","timestamp":1761870754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2152265019301247"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}